SCYNEXIS, Inc. to Present at Jefferies 2015 Antibiotic Summit
RESEARCH TRIANGLE PARK, N.C., March 12, 2015 (GLOBE NEWSWIRE) -- Drug discovery and development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that members of the SCYNEXIS executive management team will present at the Jefferies 2015 Antibiotic Summit hosted by Eun Yang at the Jefferies Offices in New York City on Wednesday, March 18, 2015, at 2:10 p.m. ET.
About SCYNEXIS, Inc.
SCYNEXIS is a pharmaceutical company committed to the discovery, development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of serious and life-threatening invasive fungal infections in humans. For more information, visit www.scynexis.com.
CONTACT: Company Chuck Osborne Chief Financial Officer Tel: 919-544-8600 E-mail: firstname.lastname@example.org Investor Relations Jillian Connell The Trout Group Tel: 646-378-2956 Email: email@example.com Media Relations Heather Savelle MacDougall Biomedical Communications Tel: 781-235-3060 E-mail: firstname.lastname@example.orgSource: SCYNEXIS, Inc.
Released March 12, 2015